NCT06707532 The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)
| NCT ID | NCT06707532 |
| Status | Recruiting |
| Phase | — |
| Sponsor | 4th Military Clinical Hospital with Polyclinic, Poland |
| Condition | Kidney Failure, Acute |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2024-08-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.
Eligibility Criteria
Inclusion Criteria: * Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation Exclusion Criteria: * Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.
Contact & Investigator
Marek Szamborski, MD
PRINCIPAL INVESTIGATOR
Senior Assistant
Frequently Asked Questions
Who can join the NCT06707532 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Kidney Failure, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06707532 currently recruiting?
Yes, NCT06707532 is actively recruiting participants. Contact the research team at mszamborski@4wsk.pl for enrollment information.
Where is the NCT06707532 trial being conducted?
This trial is being conducted at Wroclaw, Poland.
Who is sponsoring the NCT06707532 clinical trial?
NCT06707532 is sponsored by 4th Military Clinical Hospital with Polyclinic, Poland. The principal investigator is Marek Szamborski, MD at Senior Assistant. The trial plans to enroll 32 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.